- Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
- The company has also announced a new chronic kidney disease research program
- CEO Chris Moreau sat down with Shoran Devi to discuss the news
- Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
- Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55
Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).
The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.
Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.
The company has also announced a new chronic kidney disease research program.
CEO Chris Moreau sat down with Shoran Devi to discuss the news.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.
